Table 2.
The concentration of selenium, copper, zinc, copper:zinc molar ratio, and total antioxidant status in the serum of patients with Alzheimer’s disease.
| Variable | Control Group | AD Patients | p-Value | ||
|---|---|---|---|---|---|
| (n = 60) | (n = 110) | ||||
| Average ± SD | |||||
| (min–max) | |||||
| Median (Q1; Q3) | |||||
| Total | Total | ||||
| M (a) | F (b) | M (c) | F (d) | ||
| Se (μg/L) | 79.8 ± 22.0 | 69.1 ± 19.3 | <0.05 | ||
| (44.4–138.4) | (18.27–117.62) | ||||
| 73.3 (65.6; 91.6) | 71.4 (58.1; 79.7) | ||||
| 71.0 ± 13.9 | 81.7 ± 23.1 | 69.5 ± 17.9 | 68.9 ± 19.8 | c vs. d * | |
| (52.4–92.9) | (44.4–138.4) | (41.7–107.5) | (18.3–117.6) | ||
| 72.6 (58.5; 80.2) | 73.3 (66.6; 100.2) | 70.6 (52.1; 81.2) | 72.3 (58.4; 79.4) | ||
| Cu (mg/L) | 1.07 ± 0.3 | 1.03 ± 0.23 | ns | ||
| (0.68–1.94) | (0.64–2.17) | ||||
| 1.02 (0.86; 1.24) | 1.01 (0.87; 1.13) | ||||
| 0.96 ± 0.15 | 1.10 ± 0.30 | 0.90 ± 0.18 | 1.07 ± 0.23 | c vs. d * | |
| (0.70–1.12) | (0.68–1.94) | (0.65–1.27) | (0.64–2.17) | ||
| 0.97 (0.86; 1.09) | 1.02 (0.85; 1.28) | 0.87 (0.76; 1.05) | 1.04 (0.96; 1.16) | ||
| Zn (mg/L) | 0.92 ± 0.23 | 0.75 ± 0.33 | <00000.1 | ||
| (0.56–1.53) | (0.38–3.77) | ||||
| 0.86 (0.75; 1.02) | 0.71 (0.62; 0.83) | ||||
| 0.88 ± 0.27 | 0.92 ± 0.21 | 0.84 ± 0.61 | 0.71 ± 0.14 | c vs. d * | |
| (0.56–1.47) | (0.62–1.53) | (0.38–3.77) | (0.48–1.12) | ||
| 0.84 (0.73; 0.93) | 0.88 (0.75; 1.03) | 0.75 (0.60; 0.90) | 0.70 (0.63; 0.81) | ||
| Cu:Zn molar ratio | 1.24 ± 0.34 | 1.52 ± 0.47 | <0.001 | ||
| (0.60–2.07) | (0.23–3.52) | ||||
| 1.20 (1.01; 1.48) | 1.44 (1.26; 1.82) | ||||
| 1.21 ± 0.39 | 1.25 ± 0.34 | 1.31 ± 0.48 | 1.59 ± 0.45 | b vs. d * c vs. d * |
|
| (0.60–1.93) | (0.70–2.07) | (0.23–2.86) | (0.81–3.52) | ||
| 1.23 (1.00; 1.34) | 1.16 (1.01; 1.53) | 1.33 (0.99; 1.50) | 1.58 (1.33; 1.84) | ||
| TAS (mmol/L) | 1.43 ± 0.67 | 1.11 ± 0.42 | <0.01 | ||
| (0.63–3.50) | (0.27–2.96) | ||||
| 1.31 (0.99; 1.70) | 1.10 (0.83; 1.33) | ||||
| 1.88 ± 0.84 | 1.32 ± 0.59 | 1.17 ± 0.36 | 1.09 ± 0.44 | a vs. b * a vs. c * b vs. d * |
|
| (1.06–3.47) | (0.63–3.50) | (0.45–1.84) | (0.27–2.96) | ||
| 1.69 (1.16; 2.41) | 1.26 (0.94; 1.46) | 1.23 (0.93; 1.43) | 1.09 (0.79; 1.27) | ||
AD—Alzheimer’s disease, SD—standard deviation, Q1—lower quartile, Q3—upper quartile, p—level of significance, ns—no significant, M—male, F—female, a—male from control group, b—female from control group, c—male AD Patients, d—female AD Patients, TAS—total antioxidant status, * p-value < 0.05.